A study to evaluate the efficacy of CV-MG01 (Myasterix), a therapy for Myasthenia gravis
A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG01 in Patients with Moderate to Severe Myasthenia Gravis - Myasterix Efficacy Phase 2/3 Study A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the E ...
Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles.The underlying defect is a decrease in the number of available acetylcholine receptors (AChRs) at neuromuscular junctions due to an antibody-mediated autoimmune attack. MedDRA version: 19.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigabilit ...
Product Name: CV-MG01 INN or Proposed INN: Not applicable Other descriptive name: T-peptide-CRM197 conjugate INN or Proposed INN: Not applicable Other descriptive name: B-peptide-CRM197 conjugateProduct Name: CV-MG01 INN or Proposed INN: Not applicable Other descriptive name: T-peptide-CRM197 con ...
A study to evaluate the efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis
A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Subcutaneous Injections of the Myasthenia Gravis Active Targeted Immunotherapy CV-MG01 in Patients with Moderate to Severe Myasthenia Gravis - Myasterix Efficacy Phase 2/3 Study A Multi-center, Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the E ...
Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigability of skeletal muscles.The underlying defect is a decrease in the number of available acetylcholine receptors (AChRs) at neuromuscular junctions due to an antibody-mediated autoimmune attack. MedDRA version: 19.1;Level: PT;Classification code 10028417;Term: Myasthenia gravis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Myasthenia Gravis (MG) is a chronic neuromuscular disorder characterized by weakness and fatigabilit ...
Product Name: CV-MG01 INN or Proposed INN: Not applicable Other descriptive name: T-peptide-CRM197 conjugate INN or Proposed INN: Not applicable Other descriptive name: B-peptide-CRM197 conjugateProduct Name: CV-MG01 INN or Proposed INN: Not applicable Other descriptive name: T-peptide-CRM197 con ...